One of her recent patients, a man in his 80s with advanced multiple myeloma refractive to other therapies, achieved a complete response after treatment (which he received as part of a clinical trial).

Medically reviewed by Lindsay Cook, PharmD Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer ...

Perspective from Aysa Varshavsky, MD, PhD The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase ...

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...

While some patients with advanced multiple myeloma survive only a few months, the combined drug treatment resulted in a response and a significant improvement in the condition of about 80 percent ...

Allogeneic transplants also can treat multiple myeloma. When you have an allogeneic stem cell transplant ... MSK developed many of the transplant methods that are widely used today. This includes ...

Talquetamab combined with teclistamab shows a high response rate in patients with relapsed or refractory multiple myeloma, with 80% responding to the recommended phase 2 regimen.

Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

"Through our multidisciplinary effort, we aimed to develop advanced bone repair materials ... systemic and local treatment strategy for multiple myeloma. Beyond oncology, these materials may ...